You are not logged in.

Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease

Selby, Warwick, Pavli, Paul, Crotty, Brendan, Florin, Tim, Radford-Smith, Graham, Gibson, Peter, Mitchell, Brent, Connell, William, Read, Robert, Merrett, Michael, Ee, Hooi, Hetzel, David and Antibiotics in Crohn’s Disease Study Group 2007, Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease, Gastroenterology, vol. 132, no. 7, pp. 2313-2319, doi: 10.1053/j.gastro.2007.03.031.

Attached Files
Name Description MIMEType Size Downloads

Title Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease
Author(s) Selby, Warwick
Pavli, Paul
Crotty, BrendanORCID iD for Crotty, Brendan orcid.org/0000-0002-0592-235X
Florin, Tim
Radford-Smith, Graham
Gibson, Peter
Mitchell, Brent
Connell, William
Read, Robert
Merrett, Michael
Ee, Hooi
Hetzel, David
Antibiotics in Crohn’s Disease Study Group
Journal name Gastroenterology
Volume number 132
Issue number 7
Start page 2313
End page 2319
Publisher Elsevier Science
Place of publication New York, N.Y.
Publication date 2007-06
ISSN 0016-5085
1528-0012
Summary Background & Aims: Mycobacterium avium subspecies paratuberculosis has been proposed as a cause of Crohn’s disease. We report a prospective, parallel, placebo-controlled, double-blind, randomized trial of 2 years of clarithromycin, rifabutin, and clofazimine in active Crohn’s disease, with a further year of follow-up. Methods: Two hundred thirteen patients were randomized to clarithromycin 750 mg/day, rifabutin 450 mg/day, clofazimine 50 mg/day or placebo, in addition to a 16-week tapering course of prednisolone. Those in remission (Crohn’s Disease Activity Index ≤150) at week 16 continued their study medications in the maintenance phase of the trial. Primary end points were the proportion of patients experiencing at least 1 relapse at 12, 24, and 36 months. Results: At week 16, there were significantly more subjects in remission in the antibiotic arm (66%) than the placebo arm (50%; P = .02). Of 122 subjects entering the maintenance phase, 39% taking antibiotics experienced at least 1 relapse between weeks 16 and 52, compared with 56% taking placebo (P = .054). At week 104, the figures were 26% and 43%, respectively (P = .14). During the following year, 59% of the antibiotic group and 50% of the placebo group relapsed (P = .54). Conclusions: Using combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for up to 2 years, we did not find evidence of a sustained benefit. This finding does not support a significant role for Mycobacterium avium subspecies paratuberculosis in the pathogenesis of Crohn’s disease in the majority of patients. Short-term improvement was seen when this combination was added to corticosteroids, most likely because of nonspecific antibacterial effects.
Language eng
DOI 10.1053/j.gastro.2007.03.031
Field of Research 110307 Gastroenterology and Hepatology
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2007, AGA Institute Published by Elsevier Inc.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30009464

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 199 times in TR Web of Science
Scopus Citation Count Cited 218 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 953 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 13 Oct 2008, 16:00:54 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.